Correspondence | Published:

Biotech leaders call for free press

Nature Biotechnology volume 36, pages 920922 (2018) | Download Citation

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Acknowledgements

This letter represents solely the individual and personal views of the authors and signatories, and not those of their employers, companies, universities or any other organization or agency.

Author information

Affiliations

  1. Acorda Therapeutics, Ardsley, New York, USA.

    • Ron Cohen
  2. Decibel Therapeutics, Boston, Massachusetts, USA.

    • Steven Holtzman
  3. New Milford, Connecticut, USA.

    • Jeremy M Levin
  4. Alnylam Pharmaceuticals, Inc., Cambridge, Massachusetts, USA.

    • John M Maraganore
  5. Quentis Therapeutics, Inc., New York, New York, USA.

    • Michael Aberman
  6. Cydan II, Cambridge, Massachusetts, USA.

    • Chris Adams
  7. Gamida Cell, Boston, Massachusetts, USA.

    • Julian Adams
  8. Blueprint Medicines, Cambridge, Massachusetts, USA.

    • Jeffrey Albers
  9. Veracyte, Inc., South San Francisco, California, USA.

    • Bonnie Anderson
  10. Health Catalysts Group, Tucson, Arizona, USA.

    • Mara G Aspinall
  11. Constellation Pharmaceuticals, Inc., Cambridge, Massachusetts, USA.

    • James E Audia
  12. Principa Biopharma, South San Francisco, California, USA.

    • Martin Babler
  13. Caltech, Pasadena, California, USA.

    • David Baltimore
  14. Moderna, Inc., Cambridge, Massachusetts, USA.

    • Stephane Bancel
  15. Atlas Venture, Cambridge, Massachusetts, USA.

    • Peter Barrett
  16. ZappRx, Boston, Massachusetts, USA.

    • Zoe Barry
  17. MIT/Whitehead Institute, Cambridge, Massachusetts, USA.

    • David Bartel
  18. BioMarin Pharmaceutical, Novato, California, USA.

    • Jean-Jacques Bienaime
  19. Acorda Therapeutics, Inc., Ardsley, New York, USA.

    • Burkhard Blank
  20. Cytokinetics, Inc., South San Francisco, California, USA.

    • Robert I Blum
  21. Equillium, Inc., La Jolla, California, USA.

    • Daniel M Bradbury
  22. Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts, USA.

    • Eugene Braunwald
  23. Akebia Therapeutics, Cambridge, Massachusetts, USA.

    • John P Butler
  24. Novo Nordisk (retired), Seattle, Washington, USA.

    • Bruce Carter
  25. Morphic Therapeutic, Waltham, Massachusetts, USA.

    • Gustav Christensen
  26. Atara Biotherapeutics, South San Francisco, California, USA.

    • Isaac Ciechanover
  27. Genocea Biosciences, Inc., Cambridge, Massachusetts, USA.

    • Chip Clark
  28. Cardinal Partners, Princeton, New Jersey, USA.

    • John K Clarke
  29. Flexion Therapeutics, Burlington, Massachusetts, USA.

    • Michael D Clayman
  30. Graybug Vision, Redwood City, California, USA.

    • Jeffrey L Cleland
  31. Lyme Properties 2, LLC, West Lebanon, New Hampshire, USA.

    • David Clem
  32. Yumanity Therapeutics, Cambridge, Massachusetts, USA.

    • N Anthony Coles
  33. Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.

    • Charles L Cooney
  34. MassBio, Cambridge, Massachusetts, USA.

    • Robert K Coughlin
  35. Csimma LLC, Lincoln, Massachusetts, USA.

    • Zoltan Csimma
  36. IRC, CGIR, LLC, Savannah, Georgia, USA.

    • Sally J Curley
  37. Xencor, Monrovia California, USA.

    • Bassil Dahiyat
  38. ProQR Therapeutics, Cambridge, Massachusetts, USA.

    • Daniel A de Boer
  39. Aura Biosciences Inc., Cambridge Massachusetts, USA.

    • Elisabet de los Pinos
  40. Department of Cancer Biology, MD Anderson Cancer Center, Houston, Texas, USA.

    • Ronald A DePinho
  41. MaxCyte Inc., Gaithersburg Maryland, USA.

    • Douglas Doerfler
  42. Dornbusch & Company, Oakland, California, USA.

    • Daniel Dornbusch
  43. Aldeyra Therapeutics, Lexington, Massachusetts, USA.

    • Richard H Douglas
  44. Lundbeck Pharmaceuticals, København, Denmark.

    • Deborah Dunsire
  45. Third Rock Ventures, Boston, Massachusetts, USA.

    • Neil Exter
  46. PaxVax, Redwood City, California, USA.

    • Nima Farzan
  47. Atlas Venture, Cambridge, Massachusetts, USA.

    • Jean-François Formela
  48. Verastem, Inc., Needham, Massachusetts, USA.

    • Robert Forrester
  49. Cambridge BioMarketing, Boston, Massachusetts, USA.

    • Maureen N Franco
  50. Apellis Pharmaceuticals, Crestwood, Kentucky, USA.

    • Cedric Francois
  51. Blaze Bioscience Inc., Seattle, Washington, USA.

    • Heather Franklin
  52. Relypsa, a Vifor Pharma Group Company, Redwood City, California, USA.

    • Scott Garland
  53. Evelo Biosciences, Boston, Massachusetts, USA.

    • Simba Gill
  54. The Column Group, San Francisco, California, USA.

    • David V Goeddel
  55. Trevena Inc., Wayne, Pennsylvania, USA.

    • Maxine Gowen
  56. Intarcia Therapeutics, Boston, Massachusetts, USA.

    • Kurt Graves
  57. Gray Strategic Advisors, LLC, New York, New York, USA.

    • Mary Ann Gray
  58. Alnylam Pharmaceuticals, Cambridge, Massachusetts, USA.

    • Barry Greene
  59. Imbria Pharmaceuticals, Rancho Santa Fe, California, USA.

    • David-Alexandre C Gros
  60. Gossamer Bio, San Diego California, USA.

    • Faheem Hasnain
  61. Science History Institute, Philadelphia, Pennsylvania, USA.

    • Michael Hammerschmidt
  62. Redpin Therapeutics, New York, New York, USA.

    • Elma S Hawkins
  63. Hydra Biosciences, Cambridge, Massachusetts, USA.

    • Russell Herndon
  64. Nkarta Therapeutics, South San Francisco, California, USA.

    • Paul Hastings
  65. Acorda Therapeutics, Ardsley, New York, USA.

    • Andrew Hindman
  66. Cell Medica, London, UK.

    • Annalisa Jenkins
  67. Dana-Farber Cancer Institute/Harvard Medical School/MIT/Foghorn Therapeutics, Inc., Boston, Massachusetts, USA.

    • Cigall Kadoch
  68. Ultragenyx Pharmaceutical Inc., Novato, California, USA.

    • Emil D Kakkis
  69. ProMIS Neurosciences, Cambridge, Massachusetts, USA.

    • Johanne Kaplan
  70. Alnylam Pharmaceuticals, Inc., Cambridge, Massachusetts, USA.

    • Laurie Keating
  71. GlycoMimetics, Rockville, Maryland, USA.

    • Rachel King
  72. Virion Biotherapeutics LLC, London, UK.

    • Vanessa King
  73. MacroGenics Inc., Rockville, Maryland, USA.

    • Scott Koenig
  74. RA Capital Management, Boston, Massachusetts, USA.

    • Peter Kolchinsky
  75. Insitro, South San Francisco, California, USA.

    • Daphne Koller
  76. Naples, Florida, USA.

    • Marc Kozin
  77. ViaCyte, San Diego, California, USA.

    • Paul Laikind
  78. MIT, Cambridge, Massachusetts, USA.

    • Robert Langer
  79. LaVoieHealthScience, Boston, Massachusetts, USA.

    • Donna L LaVoie
  80. Decibel Therapeutics, Boston, Massachusetts, USA.

    • John J Lee
  81. Deerfield Management, New York, New York, USA.

    • Jonathan Leff
  82. Tasso, Inc., Bellevue, Washington, USA.

    • Alan Levy
  83. Harvard Medical School, Boston, Massachusetts, USA.

    • Judy Lieberman
  84. Alnylam Pharmaceuticals, Cambridge, Massachusetts, USA.

    • Christine Lindenboom
  85. Broad Institute/Howard Hughes Medical Institute/Harvard University, Cambridge, Massachusetts, USA.

    • David R Liu
  86. Assembly Biosciences, San Francisco, California, USA.

    • Uri Lopatin
  87. Global Blood Therapeutics, South San Francisco, California, USA.

    • Ted W Love
  88. MTS Health Partners, New York, New York, USA.

    • David N Low Jr
  89. Scholar Rock, Cambridge, Massachusetts, USA.

    • Nagesh K Mahanthappa
  90. Inspired Purpose Coaching LLC, Canton, Massachusetts, USA.

    • Tony Martignetti
  91. Akili Interactive Labs, Inc., Boston, Massachusetts, USA.

    • W Eddie Martucci
  92. Biocon Pharma Inc., Iselin, New Jersey, USA.

    • Kiran Mazumdar-Shaw
  93. Blueprint Medicines Corporation, Cambridge, Massachusetts, USA.

    • Tracey L McCain
  94. Pear Therapeutics, Boston, Massachusetts, USA.

    • Corey M McCann
  95. Skyworks Solutions, Inc., Woburn, Massachusetts, USA.

    • David J McLachlan
  96. KSQ Therapeutics, Cambridge Massachusetts, USA.

    • David Meeker
  97. MTS Health Partners, New York, New York, USA.

    • Ravi Mehrotra
  98. Conatus Pharmaceuticals Inc., San Diego, California, USA.

    • Steven J Mento
  99. Third Rock Ventures, Boston, Massachusetts, USA.

    • Rachel Meyers
  100. Visterra Inc., Waltham, Massachusetts, USA.

    • Gregory Miller
  101. Regenxbio Inc., Rockville, Maryland, USA.

    • Ken Mills
  102. Cognition Therapeutics, Inc., Pittsburgh, Pennsylvania, USA.

    • Kenneth I Moch
  103. Exelixis, Inc., Alameda, California, USA.

    • Michael M Morrissey
  104. PTX Partner Therapeutics, Lexington, Massachusetts, USA.

    • Robert Mulroy
  105. Boehringer Ingelheim Pharmaceuticals, Cambridge, Massachusetts, USA.

    • Imran Nasrullah
  106. Sutro Biopharma, Inc., South San Francisco, California, USA.

    • William J Newell
  107. Keryx Biopharmaceuticals, Inc., Boston, Massachusetts, USA.

    • John F Neylan
  108. Vedanta Biosciences, Cambridge, Massachusetts, USA.

    • Bernat Olle
  109. Marblehead, Massachusetts, USA.

    • Eric T Olson
  110. HealthCare Ventures, Cambridge, Massachusetts, USA.

    • Douglas E Onsi
  111. BioVentures/Egalet Corporation, Wayne, Pennsylvania, USA.

    • John E Osborn
  112. Millendo Therapeutics, Inc., Ann Arbor, Michigan, USA.

    • Julia C Owens
  113. Biogen Inc., Cambridge Massachusetts, USA.

    • Stelios Papadopoulos
  114. Karuna Pharmaceuticals, Boston, Massachusetts, USA.

    • Steve Paul
  115. Visterra, Inc., Cambridge, Massachusetts, USA.

    • Brian J G Pereira
  116. OncoPep, Inc., North Andover Massachusetts, USA.

    • Doris Peterkin
  117. Third Rock Ventures, Boston, Massachusetts, USA.

    • Cary Pfeffer
  118. Intercept, New York, New York, USA.

    • Mark Pruzanski
  119. Syros Pharmaceuticals, Inc., Cambridge, Massachusetts, USA.

    • Gerald E Quirk
  120. Ardelyx, Inc., Fremont, California, USA.

    • Michael Raab
  121. X4 Pharmaceuticals Inc., Cambridge, Massachusetts, USA.

    • Paula Ragan
  122. Ovid Therapeutics, New York, New York, USA.

    • Amit Rakhit
  123. Grail/Neurocrine Biosciences/Fate Therapeutics/Daré Bioscience/Regulus Therapeutics, Rancho Santa Fe, California, USA.

    • Bill Rastetter
  124. Translate Bio, Lexington, Massachusetts, USA.

    • Ron Renaud
  125. Atlas Venture, Cambridge, Massachusetts, USA.

    • Jason P Rhodes
  126. 5AM Ventures, Boston, Massachusetts, USA.

    • Scott M Rocklage
  127. Flagship Pioneering, Cambridge, Massachusetts, USA.

    • Michael Rosenblatt
  128. Synergenics, LLC., San Francisco, California, USA.

    • William J Rutter
  129. Venrock, Palo Alto, California, USA.

    • Camille Samuels
  130. Contravir Pharmaceuticals, Edison, New Jersey, USA.

    • James Sapirstein
  131. Ocular Therapeutix, Bedford, Massachusetts, USA.

    • Amar Sawhney
  132. Harvard University/Massachusetts General Hospital, Boston, Massachusetts, USA.

    • David Scadden
  133. Vir Biotechnology, Inc., San Francisco, California, USA.

    • George Scangos
  134. Geron Corporation, Menlo Park, California, USA.

    • John A Scarlett
  135. Broad Institute/Harvard University, Boston, Massachusetts, USA.

    • Stuart L Schreiber
  136. Lycera Corp., New York, New York, USA.

    • Paul J Sekhri
  137. Seres Therapeutics, Cambridge Massachusetts, USA.

    • Eric Shaff
  138. Puretech Health, Boston, Massachusetts, USA.

    • Bennett Shapiro
  139. Princeton University, Princeton, New Jersey, USA.

    • Thomas Shenk
  140. Syros Pharmaceuticals, Cambridge Massachusetts, USA.

    • Nancy Simonian
  141. Deerfield Management, New York, New York, USA.

    • William Slattery
  142. ReNetX Bio, New Haven, Connecticut, USA.

    • Erika R Smith
  143. Equillium, Inc., La Jolla California, USA.

    • Bruce Steel
  144. CognifiSense, Inc., Park City, Utah, USA.

    • Harald F Stock
  145. OncoResponse, Inc., Seattle, Washington, USA.

    • Clifford J Stocks
  146. Decibel Therapeutics Incorporated, Boston, Massachusetts, USA.

    • Michael Su
  147. Red Sky Partners, Cambridge, Massachusetts, USA.

    • Tim Surgenor
  148. UCB S.A., Brussels, Belgium.

    • Jean-Christophe Tellier
  149. Tracon Pharmaceuticals Inc., San Diego, California, USA.

    • Charles Theuer
  150. Alzheon, Framingham, Massachusetts, USA.

    • Martin Tolar
  151. Scripps Research Translational Institute/Molecular Medicine, La Jolla, California, USA.

    • Eric Topol
  152. Jounce Therapeutics, Inc., Cambridge, Massachusetts, USA.

    • Beth Trehu
  153. Alnylam Pharmaceuticals Inc., Cambridge, Massachusetts, USA.

    • Akshay K Vaishnaw
  154. Bio Point Group, Punta Gorda, Florida, USA.

    • Christi van Heek
  155. Unum Therapeutics Inc., Cambridge, Massachusetts, USA.

    • Michael J Vasconcelles
  156. Navitor Pharmaceuticals, Inc., Cambridge, Massachusetts, USA.

    • George P Vlasuk
  157. Biogen, Cambridge, Massachusetts, USA.

    • Michel Vounatsos
  158. ChEM-H Institute/Stanford University, Stanford, California, USA.

    • Christopher T Walsh
  159. Acorda Therapeutics, Inc., Ardsley, New York, USA.

    • Jane Wasman
  160. MTS Health Partners LP, New York, New York, USA.

    • Andrew Weisenfeld
  161. Ovid Therapeutics, New York, New York, USA.

    • Yaron Werber
  162. TScan Therapeutics, Boston Massachusetts, USA.

    • Christoph Westphal
  163. Crinetics Pharmaceuticals, San Diego, California, USA.

    • Wendell Wierenga
  164. Scottsdale, Arizona, USA.

    • Terry Winters
  165. ProMIS Neurosciences, Cambridge, Massachusetts, USA.

    • Eugene Williams
  166. Unum Therapeutics Inc., Cambridge, Massachusetts, USA.

    • Chuck Wilson
  167. Syros Pharmaceuticals, Inc., Cambridge, Massachusetts, USA.

    • Peter Wirth
  168. Irras, San Diego, California, USA.

    • Kleanthis Xanthopoulos
  169. Nuvelution Pharma, Inc., South San Francisco, California, USA.

    • Sanford (Sandy) Zweifach

Consortia

  1. the Signatories to the Statement

Authors

  1. Search for Ron Cohen in:

  2. Search for Steven Holtzman in:

  3. Search for Jeremy M Levin in:

  4. Search for John M Maraganore in:

Competing interests

John Maraganore is CEO and board member of Alnylam Pharmaceuticals, and on the board of Agios Pharmaceuticals and the Biotechnology Innovation Organization. Steve Holtzman is president, CEO and board member of Decibel Therapeutics, and on the board of Molecular Partners. Ron Cohen is president and CEO of Acorda Therapeutics and a board member of VBL Therapeutics. Jeremy Levin is an officer at Ovid Therapeutics and on the board of Lundbeck A/S, Biocon Limited and ZappRX.

Corresponding authors

Correspondence to Steven Holtzman or John M Maraganore.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nbt.4271

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing